StocksFundsScreenerSectorsWatchlists
ITCI

ITCI - Intra-Cellular Therapies Inc Stock Price, Fair Value and News

67.99USD+0.71 (+1.06%)Market Closed

Market Summary

ITCI
USD67.99+0.71
Market Closed
1.06%

ITCI Alerts

  • 5 major insider sales recently.

ITCI Stock Price

View Fullscreen

ITCI RSI Chart

ITCI Valuation

Market Cap

6.6B

Price/Earnings (Trailing)

-47.12

Price/Sales (Trailing)

14.17

EV/EBITDA

-46.45

Price/Free Cashflow

-52.88

ITCI Price/Sales (Trailing)

ITCI Profitability

EBT Margin

-29.94%

Return on Equity

-23.62%

Return on Assets

-19.18%

Free Cashflow Yield

-1.89%

ITCI Fundamentals

ITCI Revenue

Revenue (TTM)

464.4M

Rev. Growth (Yr)

50.34%

Rev. Growth (Qtr)

4.7%

ITCI Earnings

Earnings (TTM)

-139.7M

Earnings Growth (Yr)

35.09%

Earnings Growth (Qtr)

-17.81%

Breaking Down ITCI Revenue

Last 7 days

1.2%

Last 30 days

5.6%

Last 90 days

2.5%

Trailing 12 Months

15.8%

How does ITCI drawdown profile look like?

ITCI Financial Health

Current Ratio

5.41

ITCI Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023310.6M365.8M420.1M464.4M
2022102.9M138.5M188.1M250.3M
202137.6M55.7M70.6M83.8M
20209.3M13.8M18.3M22.8M
20190004.8M
2017426.0K312.3K338.7K245.8K
20160316.5K263.5K361.4K
20150466.9K247.7K153.9K
20142.3M1.9M1.3M577.3K
20133.1M2.3M2.6M2.7M
2012016.6M9.9M3.1M
201100023.4M

Tracking the Latest Insider Buys and Sells of Intra-Cellular Therapies Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 31, 2024
riggs rory b
acquired
17,992
69.2
260
-
Mar 31, 2024
van nostrand robert l
acquired
5,466
69.2
79.00
-
Mar 20, 2024
riggs rory b
acquired
371,200
18.56
20,000
-
Mar 11, 2024
hineline lawrence j.
sold
-667,587
65.9606
-10,121
svp of finance, cfo
Mar 11, 2024
mates sharon
sold
-1,341,120
65.2139
-20,565
chairman, president & ceo
Mar 11, 2024
neumann mark
sold
-481,931
65.6135
-7,345
evp, chief commercial officer
Mar 11, 2024
halstead michael
sold
-484,537
65.9683
-7,345
evp and general counsel
Mar 11, 2024
durgam suresh k.
sold
-243,482
65.5933
-3,712
evp, chief medical officer
Mar 10, 2024
halstead michael
acquired
-
-
7,345
evp and general counsel
Mar 10, 2024
durgam suresh k.
acquired
-
-
7,345
evp, chief medical officer

1–10 of 50

Which funds bought or sold ITCI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
PARK AVENUE SECURITIES LLC
reduced
-0.45
-15,000
385,000
-%
Apr 10, 2024
ATWOOD & PALMER INC
unchanged
-
-1,452
41,520
-%
Apr 10, 2024
Banque Cantonale Vaudoise
added
15.82
6,000
54,000
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
5,372
5,372
-%
Apr 09, 2024
Rise Advisors, LLC
new
-
13,010
13,010
0.01%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
added
4.44
29.00
3,252
-%
Apr 05, 2024
CWM, LLC
added
96.32
25,000
52,000
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
reduced
-8.82
-149,789
1,108,860
-%
Apr 05, 2024
GAMMA Investing LLC
added
16.47
3,380
20,552
-%
Apr 05, 2024
FIRST HAWAIIAN BANK
reduced
-2.85
-26,988
413,332
0.01%

1–10 of 47

Are Funds Buying or Selling ITCI?

Are funds buying ITCI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ITCI
No. of Funds

Unveiling Intra-Cellular Therapies Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.45%
9,094,302
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
1.83%
1,763,475
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
8,192,987
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.78%
8,319,249
SC 13G/A
Feb 06, 2023
wellington management group llp
5.71%
5,409,685
SC 13G
Feb 03, 2023
blackrock inc.
7.9%
7,449,529
SC 13G/A
Jan 10, 2023
wasatch advisors inc
-
0
SC 13G/A

Recent SEC filings of Intra-Cellular Therapies Inc

View All Filings
Date Filed Form Type Document
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
8-K
Current Report
Mar 22, 2024
4
Insider Trading
Mar 19, 2024
8-K
Current Report
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading

Peers (Alternatives to Intra-Cellular Therapies Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
358.4B
85.2B
-8.56% -9.22%
10.2
4.21
6.46% 95.94%
319.4B
60.1B
2.83% 10.88%
875.18
5.31
1.40% -97.49%
148.7B
46.5B
-6.00% -36.35%
-107.08
3.19
42.59% -114.62%
144.7B
28.2B
-2.35% 8.23%
21.54
5.13
7.09% 2.52%
85.6B
27.1B
-8.52% -16.41%
15.1
3.16
-0.60% 23.36%
15.5B
15.8B
2.74% 48.08%
-26.95
0.98
6.17% 76.47%
MID-CAP
4.2B
4.7B
2.42% -13.97%
-333.88
0.91
4.58% 90.97%
4.2B
1.7B
-12.15% -13.67%
11.75
2.51
49.61% 324.78%
3.3B
8.8B
-2.39% 21.54%
-5.54
0.37
7.79% -163.11%
1.9B
644.4M
-9.13% 1.91%
14.03
2.99
29.14% 50.51%
SMALL-CAP
1.5B
743.2M
13.10% -22.61%
-4.18
1.98
24.65% 80.36%
24.0M
70.0M
-12.61% -42.70%
-2.33
0.38
-19.54% -109.18%
19.2M
-
- 57.38%
-1.04
0.22
2882.68% -138.52%
1.2M
19.6M
-42.47% -95.17%
-0.09
0.06
80.00% 43.08%
757.7K
117.6M
-95.18% -94.26%
0
0.01
-0.79% -283.60%

Intra-Cellular Therapies Inc News

Latest updates
Defense World20 hours ago
Seeking Alpha11 Mar 202407:00 am
CNN26 Feb 202411:48 pm

Intra-Cellular Therapies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42017Q42017Q32017Q22017Q1
Revenue4.7%132,099,000126,173,000110,792,00095,306,00087,869,00071,870,00055,579,00034,996,00025,671,00022,207,00020,047,00015,878,00012,454,2917,368,5941,906,6361,083,479544,2675,05530,754114,74195,287
Operating Expenses6.6%166,196,000155,886,000157,971,000143,698,000135,281,000127,499,000143,502,000107,658,000111,675,00099,531,00089,188,00069,097,00073,787,60663,305,04866,778,95350,169,00341,829,272----
  S&GA Expenses-0.5%104,720,000105,207,000101,014,00098,923,00094,631,00088,375,000100,316,00075,460,00079,678,00070,498,00069,851,00052,584,00058,348,50452,473,57341,445,55734,096,36622,763,547----
  R&D Expenses22.2%50,774,00041,550,00049,794,00038,024,00033,862,00033,274,00038,536,00029,043,00029,458,00027,032,00017,297,00015,058,00014,298,44910,275,36825,204,85716,003,32619,065,726----
EBITDA Margin18.8%-0.30-0.37-0.50-0.73-1.02-1.58-2.32-2.94-3.38-3.66-4.25-6.16---------
Income Taxes941.9%448,00043,000135,00010,000-1,000-5,0006,00023,000-24,000-5,000-10,232---3,281--1,060,851---
Earnings Before Taxes-16.2%-28,131,000-24,215,000-42,649,000-44,043,000-44,026,000-53,507,000-86,603,000-72,114,000-85,734,000-76,931,000-68,720,000-52,735,000-60,688,796-55,183,625-63,712,258-47,407,321-40,582,851----
EBT Margin18.8%-0.30-0.37-0.50-0.73-1.02-1.58-2.32-2.95-3.39-3.67-4.26-6.18---------
Net Income-17.8%-28,579,000-24,258,000-42,784,000-44,053,000-44,026,000-53,508,000-86,603,000-72,119,000-85,734,000-76,908,000-68,744,000-52,740,000-60,699,178-55,183,625-63,712,258-47,410,602-40,582,851----
Net Income Margin18.5%-0.30-0.37-0.50-0.73-1.02-1.58-2.32-2.95-3.39-3.67-4.26-6.18---------
Free Cashflow91.9%-2,062,000-25,538,000-36,802,000-60,066,000-39,165,000-53,468,000-94,916,000-83,415,000-73,185,000-79,576,000-59,341,000-47,767,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.5%728718714722755782812869490557626674717771441481251281310343357
  Current Assets-4.9%668702698706738760789848467533601649691745419461230259288321355
    Cash Equivalents48.7%14899.0014276.0014913577.0012992.0010612113061.0030112918010810292.0064.0055.00
  Inventory-72.9%12.0043.0042.0028.0024.0024.0025.008.008.008.008.008.007.003.002.001.00-----
  Net PPE-7.5%2.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.001.001.00
Liabilities17.0%13711710795.0099.0097.0090.0076.0072.0070.0072.0062.0060.0062.0061.0051.0056.0054.0053.0054.0039.00
  Current Liabilities19.8%12410392.0080.0083.0077.0071.0059.0053.0050.0050.0040.0037.0038.0040.0031.0036.0033.0033.0033.0036.00
Shareholder's Equity-1.5%591601607628656685722793418487554612657709380430195227257289318
  Retained Earnings-1.8%-1,617-1,588-1,564-1,521-1,477-1,433-1,379-1,293-1,221-1,135-1,058-989-937-876-821-757-710-669-634-597-562
  Additional Paid-In Capital0.8%2,2082,1912,1742,1522,1382,1242,1072,0891,6391,6221,6121,6021,5931,5851,2001,188905896891886881
Shares Outstanding0.2%96.0096.0096.0096.0095.0094.0094.0093.0081.0081.0081.0081.00---------
Float---6,000-------5,300---3,200---614--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations91.8%-2,061-25,270-36,802-60,066-39,193-53,351-94,793-82,849-73,184-79,267-59,326-47,767-68,242-63,579-47,024-51,226-35,055-29,989-27,308-35,629-29,161
  Share Based Compensation3.8%14,85614,31113,22610,43911,15911,75111,9988,1059,3789,5308,6176,7784,7636,9016,9475,5045,9394,8074,9875,0554,425
Cashflow From Investing335.1%47,422-20,16794,748-16,46250,263106,17037,229-322,03551,50963,77248,794116,269-176,335-143,216-7,757-152,98437,73740,23754,72244,74214,146
Cashflow From Financing16.4%3,0042,5818,5853,6402,1875,6545,504441,8147,9145911,5821,4323,635378,4944,480277,5672,79315225931.00186

ITCI Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total revenues, net$ 464,370$ 250,314$ 83,803
Operating expenses:   
Cost of product sales33,74520,4438,035
Selling, general and administrative409,864358,782272,611
Research and development180,142134,71588,845
Total operating expenses623,751513,940369,491
Loss from operations(159,381)(263,626)(285,688)
Interest income20,3437,3761,568
Loss before provision for income taxes(139,038)(256,250)(284,120)
Income tax expense(636)(6)(6)
Net loss$ (139,674)$ (256,256)$ (284,126)
Net loss per common share:   
Basic (in dollars per share)$ (1.46)$ (2.72)$ (3.50)
Diluted (in dollars per share)$ (1.46)$ (2.72)$ (3.50)
Weighted average number of common shares:   
Basic (in shares)95,881,72994,046,67081,253,394
Diluted (in shares)95,881,72994,046,67081,253,394
Product sales, net   
Total revenues, net$ 462,175$ 249,132$ 81,708
Grant revenue   
Total revenues, net$ 2,195$ 1,182$ 2,095

ITCI Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 147,767$ 148,615
Investment securities, available-for-sale350,174443,290
Restricted cash1,7501,750
Accounts receivable, net114,01875,189
Inventory11,64723,920
Prepaid expenses and other current assets42,44345,193
Total current assets667,799737,957
Property and equipment, net1,6541,913
Right of use assets, net12,92814,824
Inventory, non-current38,6210
Other assets7,29386
Total assets728,295754,780
Current liabilities:  
Accounts payable11,45210,395
Accrued and other current liabilities27,94419,657
Accrued customer programs53,17325,621
Accrued employee benefits27,36422,996
Operating lease liabilities3,6124,567
Total current liabilities123,54583,236
Operating lease liabilities, non-current13,32615,474
Total liabilities136,87198,710
Stockholders’ equity:  
Common stock, $0.0001 par value: 175,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 96,379,811 and 94,829,794 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively109
Additional paid-in capital2,208,4702,137,737
Accumulated deficit(1,617,160)(1,477,486)
Accumulated comprehensive income (loss)104(4,190)
Total stockholders’ equity591,424656,070
Total liabilities and stockholders’ equity$ 728,295$ 754,780
ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
 CEO
 WEBSITEintracellulartherapies.com
 INDUSTRYPharmaceuticals
 EMPLOYEES561

Intra-Cellular Therapies Inc Frequently Asked Questions


What is the ticker symbol for Intra-Cellular Therapies Inc? What does ITCI stand for in stocks?

ITCI is the stock ticker symbol of Intra-Cellular Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intra-Cellular Therapies Inc (ITCI)?

As of Thu Apr 11 2024, market cap of Intra-Cellular Therapies Inc is 6.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers. The fair value of Intra-Cellular Therapies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intra-Cellular Therapies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITCI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intra-Cellular Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether ITCI is over valued or under valued. Whether Intra-Cellular Therapies Inc is cheap or expensive depends on the assumptions which impact Intra-Cellular Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITCI.

What is Intra-Cellular Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, ITCI's PE ratio (Price to Earnings) is -47.12 and Price to Sales (PS) ratio is 14.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITCI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intra-Cellular Therapies Inc's stock?

In the past 10 years, Intra-Cellular Therapies Inc has provided 0.15 (multiply by 100 for percentage) rate of return.